These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2788032)

  • 1. Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2.
    Brown RR; Lee CM; Kohler PC; Hank JA; Storer BE; Sondel PM
    Cancer Res; 1989 Sep; 49(17):4941-4. PubMed ID: 2788032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tryptophan degradation in patients with gynecological cancer correlates with immune activation.
    Schroecksnadel K; Winkler C; Fuith LC; Fuchs D
    Cancer Lett; 2005 Jun; 223(2):323-9. PubMed ID: 15896467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of immune activation using biochemical changes in a porcine model of cardiac arrest.
    Amann A; Widner B; Rieder J; Antretter H; Hoffmann G; Mayr V; Strohmenger HU; Fuchs D
    Mediators Inflamm; 2001 Dec; 10(6):343-6. PubMed ID: 11817676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment.
    Werner-Felmayer G; Werner ER; Fuchs D; Hausen A; Reibnegger G; Wachter H
    Cancer Res; 1990 May; 50(10):2863-7. PubMed ID: 2110500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
    Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
    Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased plasma tryptophan in pregnancy.
    Schröcksnadel H; Baier-Bitterlich G; Dapunt O; Wachter H; Fuchs D
    Obstet Gynecol; 1996 Jul; 88(1):47-50. PubMed ID: 8684760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
    Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
    Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon].
    Aulitzky W; Gastl G; Troppmair J; Tilg H; Abbrederis K; Nerl C; Flener R; Rokos H; Huber C
    Acta Med Austriaca; 1985; 12(5):115-21. PubMed ID: 3832745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
    McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
    Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased degradation of tryptophan in blood of patients with rheumatoid arthritis.
    Schroecksnadel K; Kaser S; Ledochowski M; Neurauter G; Mur E; Herold M; Fuchs D
    J Rheumatol; 2003 Sep; 30(9):1935-9. PubMed ID: 12966593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
    Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
    Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
    Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
    Lissoni P; Barni S; Ardizzoia A; Scardino E; Tancini G; Viganò MG
    J Biol Regul Homeost Agents; 1995; 9(1):21-3. PubMed ID: 8553904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum tryptophan concentration in pollinosis patients is associated with unresponsiveness to pollen extract therapy.
    Kositz C; Schroecksnadel K; Grander G; Schennach H; Kofler H; Fuchs D
    Int Arch Allergy Immunol; 2008; 147(1):35-40. PubMed ID: 18446051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
    Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age.
    Frick B; Schroecksnadel K; Neurauter G; Leblhuber F; Fuchs D
    Clin Biochem; 2004 Aug; 37(8):684-7. PubMed ID: 15302611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection.
    Fuchs D; Möller AA; Reibnegger G; Werner ER; Werner-Felmayer G; Dierich MP; Wachter H
    Immunol Lett; 1991 Jun; 28(3):207-11. PubMed ID: 1909303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
    Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
    J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bariatric surgery cannot prevent tryptophan depletion due to chronic immune activation in morbidly obese patients.
    Brandacher G; Winkler C; Aigner F; Schwelberger H; Schroecksnadel K; Margreiter R; Fuchs D; Weiss HG
    Obes Surg; 2006 May; 16(5):541-8. PubMed ID: 16687019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.